title: Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
abstract: Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patients were assessed by means of the Montgomery-Asberg Depression Rating Scale (MADRS), the 17 items Hamilton Depression Rating Scale (HAMD) and the investigator's Clinical Global Impressions (CGI), Observed and spontaneously reported adverse events were also recorded. A total of 357 patients of both sexes, aged between 21 and 73 years, entered the double-blind phase of the trial. A clear reduction of both the MADRS and the HAMD mean total scores was observed in both treatment groups with no statistically significant differences between treatments. Apart from back pain recorded more frequently in the citalopram group, no significant difference was found between the two treatment groups with regard to adverse events, and both citalopram and fluoxetine were considered to be well tolerated. It was concluded that citalopram was as effective as fluoxetine in the treatment of unipolar major depression. Citalopram showed an earlier onset of recovery than fluoxetine.
authors.affiliation: Clinique de Psychiatrie, Hospices Civils de Strasbourg, France.
authors.forename: M
authors.initials: M
authors.lastname: Patris
authors.forename: J M
authors.initials: JM
authors.lastname: Bouchard
authors.forename: T
authors.initials: T
authors.lastname: Bougerol
authors.forename: J F
authors.initials: JF
authors.lastname: Charbonnier
authors.forename: J F
authors.initials: JF
authors.lastname: Chevalier
authors.forename: G
authors.initials: G
authors.lastname: Clerc
authors.forename: C
authors.initials: C
authors.lastname: Cyran
authors.forename: P
authors.initials: P
authors.lastname: Van Amerongen
authors.forename: O
authors.initials: O
authors.lastname: Lemming
authors.forename: H E
authors.initials: HE
authors.lastname: Høpfner Petersen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D015283:Citalopram; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors